Tolerability of beta-blocker initiation and titration with bisoprolol and carvedilol in congestive heart failure -- a randomized comparison

Cardiology
Søren GalatiusPer R Hildebrandt

Abstract

In clinical trials beta-blockers (BB) are well tolerated in patients with systolic congestive heart failure (CHF). In contrast, in daily practice treatment initiation and titration appear to be more difficult and may differ in various BB -- but systematic data are lacking. We randomized 87 patients with systolic CHF (mean age 70.1 +/- 10.6 years, 24% females, LVEF 0.28 +/- 0.10, NYHA III-IV 29%) to treatment with either bisoprolol or carvedilol, in order to assess and compare the maximally achievable number of patients on treatment with these BB and the maximally achieved dosage during a minimum of 2 months attendance at our out patient heart failure clinic. In those randomized to bisoprolol, mean dose at 2 months was 33% of target dose (3.1 +/- 2.6 mg) and 41% at discharge. In those on carvedilol, the mean dose at 2 months was 27% of target dose (13.4 +/- 14.0 mg) and 32% at discharge. Thirty-nine and 40% of the bisoprolol and carvedilol treated patients, respectively, had stopped treatment at discharge. None of the figures differed significantly between the two treatment groups and no baseline parameter predicted BB tolerability. Thus, almost twice the number of unselected patients with systolic CHF attending a heart failure ...Continue Reading

References

Aug 9, 2001·European Heart Journal·W J RemmeUNKNOWN Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology
Oct 23, 2002·Circulation·Milton PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Feb 15, 2003·JAMA : the Journal of the American Medical Association·Henry KrumUNKNOWN Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group
Jun 20, 2003·Journal of Cardiac Failure·Javed ButlerJohn R Wilson

❮ Previous
Next ❯

Citations

Jan 19, 2008·Expert Opinion on Pharmacotherapy·Jens Rosenberg, Finn Gustafsson
Aug 25, 2005·Scandinavian Cardiovascular Journal : SCJ·Mogens K AndersenFinn Gustafsson
May 16, 2008·The American Journal of the Medical Sciences·Elamin M ElaminUNKNOWN S.T.I.T.C.H.D. STUDY GROUP
Oct 2, 2009·Revista española de cardiología·José M Verdú RotellarMar Domingo
Apr 24, 2010·Journal of the American College of Cardiology·Andrew JabbourChristopher S Hayward
May 6, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Johanna EdlmayrRudolf Valenta
Apr 24, 2017·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Hanna FröhlichLutz Frankenstein
Feb 10, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sivaraman PadavattanZora Markovic-Housley
Aug 21, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alexandra BaarRudolf Valenta
Apr 16, 2002·The Journal of Biological Chemistry·Jesper E MogensenDaniel E Otzen
Apr 11, 2020·Life Sciences·Xiao-Fang Li, Yi-Min Mao

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.